Ceftolozane/Tazobactam Susceptibility in ESBL-Producing Enterobacterales: Insights from the SMART Program 2020–2022 in China
Infection and Drug Resistance · 2026-09 · Volume 19 · 1-12
DOI: 10.2147/idr.s624172 ↗Kurz gefasst
Fachartikel in der Zeitschrift Infection and Drug Resistance, 2026-09. Verfasst von Yanfei Wang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious Diseases, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, 310016, People's Republic …. Die Arbeit wurde bisher 1-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Infectious Diseases, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, 310016, People's Republic of China.
- Department of Clinical Laboratory, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, 310016, People's Republic of China.
- Value & Implementation, MSD China, Shanghai, 200030, People's Republic of China.
- Zhejiang Provincial Engineering Research Center of Innovative Instruments for Precise Pathogen Detection, Hangzhou, Zhejiang, 310016, People's Republic of China.
Zitieren
APA
Wang, Y., Zhang, Y., Quan, J., Fu, Y., Zhou, Z., Xia, J., & Yu, Y. (2026). Ceftolozane/Tazobactam Susceptibility in ESBL-Producing Enterobacterales: Insights from the SMART Program 2020–2022 in China. Infection and Drug Resistance, Volume 19, 1-12. https://doi.org/10.2147/idr.s624172
Vancouver
Wang Y, Zhang Y, Quan J, Fu Y, Zhou Z, Xia J, et al. Ceftolozane/Tazobactam Susceptibility in ESBL-Producing Enterobacterales: Insights from the SMART Program 2020–2022 in China. Infection and Drug Resistance. 2026;Volume 19:1-12. doi:10.2147/idr.s624172
BibTeX
@article{Wang2026,
author = {Wang, Yanfei and Zhang, Yuke and Quan, Jingjing and Fu, Ying and Zhou, Zhihui and Xia, Jiaqi and Yu, Yunsong},
title = {Ceftolozane/Tazobactam Susceptibility in ESBL-Producing Enterobacterales: Insights from the SMART Program 2020–2022 in China},
journal = {Infection and Drug Resistance},
year = {2026},
volume = {Volume 19},
pages = {1--12},
doi = {10.2147/idr.s624172}
}
EUVIMED